Proactive Investors - Run By Investors For Investors

Hemogenyx Pharmaceuticals chief to present at immunotherapy conference

The address will highlight the fact that despite numerous advances in understanding AML, treatment remains “unsatisfactory”
Hemogenyx Pharmaceuticals chief to present at immunotherapy conference
The event takes place in the winter resort of Whistler in March

HemoGenyx Pharmaceuticals PLC (LONHEMO) chief Dr Vladislav Sandler is set to present at a cancer immunotherapy conference in March.

At the Keystone Symposia on Molecular and Cellular Biology in Canada, he will provide an overview of the development of the company's CDX antibodies.

READ: Hemogenyx set for talks over potential licensing deal with global pharma later this month

Specifically, he will assess the potential benefit of using these antibodies for the treatment of acute myeloid leukaemia (AML) as well as the conditioning of patients for hematopoietic stem cell transplantation.

Sandler’s address will go on to highlight the fact that, despite numerous advances in understanding AML, treatment remains “unsatisfactory” and that relapsed or refractory forms of the disease are nearly always fatal.

The conference takes place in the winter resort of Whistler from March 10 to 14.

In late afternoon trading, shares in Hemogenyx were 1.6% higher at 3.25p.

In a note to clients, analysts at ‘house’ broker Northland Capital commented: “This conference is a good arena to showcase Hemogenyx’s novel therapies, as it brings together leading experts in the cancer immunotherapy sector.”

For more details click here.

 -- Adds share price, analyst comment --

View full HEMO profile View Profile

HemoGenyx Pharmaceuticals Timeline

Related Articles

blood
January 29 2019
"With multiple collaboration agreements and investment from industry we view the company as undervalued," says Northland

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use